- Home
- HALO
as 09-16-2025 4:00pm EST
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 7.6B | IPO Year: | N/A |
| Target Price: | $70.25 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 4.37 | EPS Growth: | 68.93 |
| 52 Week Low/High: | $42.01 - $77.59 | Next Earning Date: | 10-30-2025 |
| Revenue: | $1,178,672,000 | Revenue Growth: | 34.97% |
| Revenue Growth (this year): | 32.57% | Revenue Growth (next year): | 23.25% |
Stock Insider Trading Activity of Halozyme Therapeutics Inc. (HALO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| LaBrosse Nicole | HALO | SVP, CHIEF FINANCIAL OFFICER | Sep 10 '25 | Sell | $75.61 | 20,000 | $1,514,267.12 | 37,546 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Sep 4 '25 | Sell | $74.36 | 20,000 | $1,480,772.20 | 736,019 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Sep 3 '25 | Sell | $74.43 | 20,000 | $1,488,726.00 | 736,019 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Sep 2 '25 | Sell | $73.44 | 20,000 | $1,475,128.09 | 736,019 | |
| Connaughton Bernadette | HALO | Director | Sep 2 '25 | Sell | $73.15 | 4,000 | $294,736.24 | 46,952 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Aug 13 '25 | Sell | $64.49 | 20,000 | $1,286,350.52 | 736,019 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Aug 12 '25 | Sell | $63.62 | 20,000 | $1,270,121.12 | 736,019 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Aug 11 '25 | Sell | $63.30 | 20,000 | $1,260,916.97 | 736,019 | |
| Torley Helen | HALO | PRESIDENT AND CEO | Jun 20 '25 | Sell | $53.14 | 60,000 | $3,185,279.82 | 736,019 |
Latest Halozyme Therapeutics Inc. News
HALO Breaking Stock News: Dive into HALO Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Does Halozyme Stock Offer More Potential After Its Recent Strong Price Run in 2025?
Investor's Business Daily
8 days ago
Dianthus Therapeutics Stock Earns RS Rating Upgrade
Zacks
8 days ago
Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion
Zacks
11 days ago
Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings
Zacks
11 days ago
Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns
MT Newswires
12 days ago
Halozyme Therapeutics Insider Sold Shares Worth $4,444,626, According to a Recent SEC Filing
Argus Research
3 months ago
HALO: Raising target price to $59.00
PR Newswire
3 months ago
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Compare HALO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HALO Halozyme Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.